Anavex drops after pulling EU marketing application for Alzheimer's therapy
Source: SeekingAlpha
2026-03-25 07:57:39 ET
More on Anavex Life Sciences
- Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory
- Anavex Life Sciences Corp. (AVXL) Q1 2026 Earnings Call Transcript
- Anavex And Alzheimer's Disease: The Future Never Seems To Be Now
- Anavex outlines regulatory milestones for blarcamesine in 2026 while advancing ACCESS-AD participation
- Anavex Life Sciences GAAP EPS of -$0.06 beats by $0.05
Read the full article on Seeking Alpha
For further details see:
Anavex drops after pulling EU marketing application for Alzheimer’s therapy
Anavex Life Sciences Corp.
NASDAQ: AVXL
AVXL Trading
-1.96% G/L:
$2.805 Last:
851,372 Volume:
$2.835 Open:
AVXL Latest News
AVXL Stock Data
$387,970,315
82,292,521
0.31%
73
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
